Seeking Alpha

TripleTheMarket's  Instablog

TripleTheMarket
Send Message
I am a former stockbroker, now with a "regular 9 to 5" career outside the financial industry. I have been following stocks for 20 years, and came across a momentum-based system for stock picking. These picks have done well for me personally, so I have decided to share them on my web... More
My blog:
Triple The Market
View TripleTheMarket's Instablogs on:
  • LULU Creeps Up...Again

    LULU product

    Lululemon Athletica is up. Again. The Tiffany’s of the fitness and yoga world is creeping up the charts. LULU makes workout gear for yoga and running. Most women i know that wear LULU gear say that it is also fashionable enough to wear after the gym as well while they run their errands. In my gym, the women wear LULU or don’t show up at all (slight exaggeration here!).

    According to Capital IQ, as of February 21st, institutions own 75.67% of this stock, and insiders own 32.72%. The CEO owns 32.5% of that number. Somehow, the two numbers add up to over 100%, but you can direct those questions to Capital IQ!

    This is the biggest company in a niche market with a high quality product. If they choose to expand their product line, look out!

    Disclosure: I own LULU.

    Mar 09 12:32 PM | Link | Comment!
  • Stock of the Day - LRN
    I frequently profile stocks that are climbing on the "Triple" radar screen.  Today I'm highlighting LRN.  

    LRN was founded in 200 and headquartered in Virginia.  The company provides curriculum services for grades K through 12 with a heavy online presence.  They have online classes and curriculum for public and private schools.  According to their website, "K¹² is America's largest provider of online education for grades K-12."

    Here is a video about home schooling with LRN in the Bay Area:

    <embed width="576" height="324" src="media.nbcbayarea.com/designvideo/embedde...; flashvars="v=http%3A%2F%2Fwww.nbcbayarea.com%2Fi%2Fembed_new%2F%3Fcid%3D102026593%26path%3D%2Fnews%2Flocal%2F" allowFullScreen="true" AllowScriptAccess="always" /> <p style="font-size:small">View more videos at: <a href="www.nbcbayarea.com/?__source=embedCode";>nbcbayarea.com<;;/a>.</p>

    On February 9th, shares jumped 10% on revenue guidance provided by the company.  From an <a href="finance.yahoo.com/news/K12-revenue-outlo...;>AP News story</a>, "Revenues rose 38.4 percent to $129 million in the quarter, and the Herndon, Va., company said it expects revenue of $515 to $520 million for the year, up from $384.5 million last year. That forecast easily topped Wall Street's revenue expectation of $504.2 million."

    Here's <a href="www.fool.com/investing/general/2011/02/0...;>another article</a> from the fools at The Motley Fool that came out on the same day.

    Now the most important part of the story, the stock price.  Below is a 1 year chart for LRN:

    <img src="app.quotemedia.com/quotetools/getChart?w...; alt="LRN 1 year" />

    Average volume is 179K.  Keep an eye on this one, and happy stock picking!

    Disclosure:  I do not own LRN.
    Feb 26 12:53 PM | Link | Comment!
  • HTWR (Heartware) - The Little Stock That Could

    Heartware, based in Framingham, MA is a major player in the treatment of congestive heart failure. It’s main product is a left ventricular assist device, and it has won recent approval to begin trials of its miniaturized device, as seen here:

    HTWR device

    A major competitor to Heartware is Thoratec (NASDAQ:THOR). Although this article from the Toronto Star posted on January 31 states that “Management appears concerned with the growing threat from a new HeartWare ventricular assist device (VAD). HeartWare recently made a splash at a major medical conference with solid bridge-to-transplant data that compared favorably to Thoratec’s HeartMate II data. With a smaller device size and easier surgical technique, we suspect HeartWare will steal market share from Thoratec during the next several years until Thoratec can introduce significant new VAD products.”

    The data below are from Thoratec’s Heartmate II device. As you can see, the survival rates greatly exceed medical management, and with Heartware’s data looking more favorable, the stock is worth a look:

    Heartmate II Survival Rate

    Now, the reason why we’re all reading this…the stock! Here is a comparison of THOR vs HTWR over the past year:

    THOR

    HTWR 1 year

    HTWR currently trades at 90.25, with a 52-week low of 37.73. This stock does not get a lot of volume (average 134K shares traded daily), but is worth a look for your portfolio. This came up on my screener a year ago, and as a momentum play, you can clearly see the outcome!

    Disclosure: I own HTWR stock.

    Feb 21 8:53 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.